Skip to main content

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Completed · Phase 2 · NCT04014075

Conditions: Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ

At a glance

Research payments reported, 2025
$49,448
U.S. investigators named
3
Sites paid
3
Planned or actual enrollment
79

About the trial

Sponsor
Daiichi Sankyo (with AstraZeneca)
Tested
Trastuzumab deruxtecan (drug)
Dates
Started 2019-11-26; completion 2024-02-13
Results posted
Yes

This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer. They must have human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction (GEJ) cancer: * that cannot be removed surgically * that has moved to other parts of the body * that got worse during or after treatment that included trastuzumab The study will enroll about 80 participants. Sites will be in North America and the European Union.

From ClinicalTrials.gov, last updated 2025-04-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Daiichi Sankyo Inc. reported $49,448 in research payments for this study in 2025 (5 payments).

Products named: Enhertu

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • David H Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center $28,444
  • Ut MD Anderson Cancer Center $14,848
  • Pacific Cancer Care $6,156

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.